Under the agreement, the companies will make the technology available to third parties and share in the revenue. The terms of the agreement were kept confidential.
Avalanche chief executive officer Thomas Chalberg said, "By making our combined technology available to third parties, we hope to allow the entire AAV field to benefit from this best-in-class production process."
The partnership will focus on the development and high-yield production of AAV vectors based on a novel technology that uses stable baculovirus.
This technology was licensed by Avalanche from Virovek, who will also play a key role in the collaboration, the companies said.